In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Cardiac dysfunction is the main mechanism of aggravation of exercise intolerance in homozygous sickle cell disease patients

Session Interplay between exercise and cardiac pathology

Speaker Alexandre Ceccaldi

Event : ESC Congress 2016

  • Topic : preventive cardiology
  • Sub-topic : Exercise Testing
  • Session type : Moderated Posters

Authors : A Ceccaldi (Paris,FR), S Hatem (Paris,FR), F Lionnet (Paris,FR), K Stankovic Stojanovic (Paris,FR), R Isnard (Paris,FR), N Hammoudi (Paris,FR)

Authors:
A. Ceccaldi1 , S. Hatem1 , F. Lionnet2 , K. Stankovic Stojanovic2 , R. Isnard1 , N. Hammoudi1 , 1Hospital Pitie-Salpetriere, Cardiology - Paris - France , 2Hospital Tenon - Paris - France ,

Citation:
European Heart Journal ( 2016 ) 37 ( Abstract Supplement ), 26

Background: Sickle cell disease (SCD) is the most frequent genetic hemoglobinopathy worldwide associated with a marked exercise intolerance. Mechanisms underlying this exercise limitation are multifactorial, complex and difficult to discriminate in clinical practice.

Purpose: To examine the role of cardiac dysfunction in the exercise limitation in homozygous SCD patients.

Methods: 60 SCD patients (32.9±10.6 years, 36 women) with dyspnea and 20 controls matched for age and gender underwent a stress echocardiography combined with gas exchange measurements during a symptom-limited exercise ramp protocol. Peak exercise oxygen uptake indexed to weight (VO2) and peak cardiac index (Ci) were measured. The difference between arterial and venous oxygen content (Ca-vO2) was calculated using Fick principle.

Results: Compared to controls, SCA patients exhibited a low peak VO2 (19.6±4.1 vs. 36.4±9.5 ml/min/kg; p<0.001), a dramatic decrease in Ca-vO2 (7.5±1.5 vs. 15.8±3.1 ml/dl; p<0.0001) whereas Ci was markedly increased (9.6±1.6 vs. 8.4±1.6 l/min/m2; p=0.005) suggesting a compensatory mechanism of the reduced peripheral oxygen transfer.

The SCD patients were next classified in tertiles according to peak VO2. While hemoglobin level and Ca-vO2 were similar, SCD patients in the lower tertile of VO2 exhibited a reduced peak Ci (Table 1). In multivariable analysis, older age and left atrial function as assessed by peak longitudinal strain were independently related to exertional intolerance.

Conclusion: The exercise intolerance of SCD patients is mainly related to the impairment of Ca-vO2 which is compensated by a high cardiac output.

However, the aggravation of exertional intolerance in SCD is due to the alteration of cardiac function related to ageing and to left atrial function deterioration.

Table 1
Lower VO2 tertileOther VO2 tertilesp value
(n=20)(n=40)
Age (years)40.3±10.129.2±8.80.0001
Peak Cardiac index (l/min/m2)8.6±1.010.1±1.70.0001
Peak Ca-vO2 (ml/dl)7.0±1.47.8±1.50.07
Hemoglobin (g/dl)8.3±1.38.8±1.20.13
LV diastolic volume index (ml/m2)91.9±23.092.2±21.50.95
LV ejection fraction at rest (%)60.7±7.962.2±5.10.46
Cardiac index at rest (l/min/m2)4.5±0.94.3±0.80.38
Tricuspid velocity at rest (m/s)2.5±0.32.4±0.20.28
Left atrial volume index at rest (ml/m2)54.7±16.944.0±11.30.02
Left atrial longitudinal strain at rest (%)30.7±5.438.9±7.2<0.0001
VO2 <16.1 ml/min/kg in women (n=12), VO2 <19.2 ml/min/kg in men (n=8). VO2 ≥16.1 ml/min/kg in women (n=24), VO2 ≥19.2 ml/min/kg in men (n=16).

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are